The project supports the company's research and development investments to complete the late stage development (clinical, regulatory, and manufacturing) of ISA101b - a synthetic long peptide (SLP) targeting human papilloma viruses (HPV) - in two HPV-induced therapeutic areas i.e. cervical, head and neck cancer.
The proceeds from the EIB loan will be used to co-finance the project, which - if successful - will create new treatment options for patients suffering from these diseases, thereby addressing a substantial unmet medical need, and saving and improving the lives of thousands of patients. The project will also contribute to the growth of a European biopharmaceutical company and the creation of new high-skilled jobs.
The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under Directive 2014/52/EU amending the Directive 2011/92/EC. However, full environmental details verified during the appraisal are aligned with best practices.
The promoter has been assessed by the EIB as being a private company not being subject to EU rules on public procurement or concessions.
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).
News & Stories
General enquiries and comments
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.
Zero tolerance against fraud and corruption
The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.